KRRONasdaqPharmaceutical PreparationsFiscal year ends December 31
Korro Bio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$8.91+0.42 (+4.95%)
Close on Oct 19, 2026
- Market cap
- $156.98M
- P/E (TTM)
- –
- Dividend yield
- –
Korro Bio statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Korro Bio | Industry median |
|---|---|---|
| Market Cap | $131.21M | $166.30M |
| Enterprise Value | $16.17M | $88.19M |
| PS Ratio | 55.08 | 3.65 |
Enterprise value
| Measure | Korro Bio | Industry median |
|---|---|---|
| EV / Sales | 6.79 | 2.51 |
Income (trailing twelve months)
| Measure | Korro Bio | Industry median |
|---|---|---|
| Revenue | $2.38M | $58.34M |
| Operating Income | -$110.18M | -$21.40M |
| Pretax Income | -$105.81M | -$14.34M |
| Net Income | -$106.64M | -$22.46M |
| EBITDA | -$110.18M | -$16.91M |
| EPS (Diluted) | -$10.00 | -$0.83 |
Margins
| Measure | Korro Bio | Industry median |
|---|---|---|
| Operating Margin | -4625.5% | -44.0% |
| Pretax Margin | -4441.9% | -13.3% |
| Profit Margin | -4477.1% | -40.2% |
| EBITDA Margin | -4625.5% | -30.2% |
| FCF Margin | -2865.9% | -9.27% |
Returns
| Measure | Korro Bio | Industry median |
|---|---|---|
| Return on Assets (ROA) | -62.0% | -40.9% |
| Return on Capital Employed (ROCE) | -73.1% | -38.1% |
Growth
| Measure | Korro Bio | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -62.1% | 5.96% |
| Revenue Growth (5Y CAGR) | -29.6% | 6.48% |
Balance sheet
| Measure | Korro Bio | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $115.04M | $61.43M |
| Net Cash (Debt) | $115.04M | $15.35M |
| Net Cash Per Share | $7.81 | $0.66 |
| Working Capital | $108.00M | $76.81M |
Financial position
| Measure | Korro Bio | Industry median |
|---|---|---|
| Current Ratio | 9.55 | 3.34 |
| Quick Ratio | 9.11 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Korro Bio | Industry median |
|---|---|---|
| Operating Cash Flow | -$67.95M | -$12.35M |
| Capital Expenditures | -$317.00K | -$1.08M |
| Free Cash Flow | -$68.27M | -$20.22M |
| FCF Per Share | -$4.64 | -$0.42 |
Efficiency
| Measure | Korro Bio | Industry median |
|---|---|---|
| Asset Turnover | 0.01 | 0.39 |
| Revenue Per Employee | $41.07K | $404.87K |
| Profits Per Employee | -$1.84M | -$703.34K |
| Employee Count | 58 | 74 |
Dividends and yields
| Measure | Korro Bio | Industry median |
|---|---|---|
| Earnings Yield | -81.3% | -23.3% |
| FCF Yield | -52.0% | -8.72% |
Shares
| Measure | Korro Bio | Industry median |
|---|---|---|
| Shares Outstanding | 14,725,600 | 58,127,000 |
| Shares Change (YoY) | 28.3% | 10.9% |
| Shares Change (QoQ) | 1.96% | 0.54% |
| Float | 10,673,600 | 49,136,700 |
| Shares Held by Insiders | 27.5% | 11.6% |
| Shares Held by Institutions | 102.4% | 59.4% |
Taxes
| Measure | Korro Bio | Industry median |
|---|---|---|
| Income Tax | $839.00K | $79.87K |
Scores
| Measure | Korro Bio | Industry median |
|---|---|---|
| Altman Z-Score | -3.73 | -0.22 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Korro Bio's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.